365216-79-1

Basic information

• Product Name: methyl 2-(4-chlorobenzoyl)-1,2,3,4-tetrahydro-9H-pyrido-[3,4-b]indole-3-carboxylate
• Synonyms: methyl 2-(4-chlorobenzoyl)-1,2,3,4-tetrahydro-9H-pyrido-[3,4-b]indole-3-carboxylate
• CAS NO: 365216-79-1
• Molecular Weight: 368.82
• Mol File: 365216-79-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 2-(4-chlorobenzoyl)-1,2,3,4-tetrahydro-9H-pyrido-[3,4-b]indole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(4-chlorobenzoyl)-1,2,3,4-tetrahydro-9H-pyrido-[3,4-b]indole-3-carboxylate(365216-79-1)
• EPA Substance Registry System: methyl 2-(4-chlorobenzoyl)-1,2,3,4-tetrahydro-9H-pyrido-[3,4-b]indole-3-carboxylate(365216-79-1)

Safety Data

• Hazardous Substances Data: 365216-79-1(Hazardous Substances Data)

Upstream product

• 7524-52-9 (S)-tryptophan methyl ester hydrochloride 
• 122-01-0 4-chloro-benzoyl chloride 
• 79815-18-2 methyl (3S)-1,2,3,4-tetrahydro-β-carboline-3-carboxylate 

Downstream Products

• 1422376-89-3 2-(4-chlorobenzoyl)-9-methyl-1,2,3,4-tetrahydropyrido[3,4-b]indole-3-carboxylic acid 
• 1422377-25-0 [3-(4-chlorophenyl)-6-methyl-6,11-dihydro-5H-indolizino[6,7-b]indole-1,2-diyl]bis-(methylene) 
• 1422377-16-9 [3-(4-chlorophenyl)-6-methyl-6,11-dihydro-5H-indolizino [6,7-b]indole-1,2-diyl]bis(methylene)bis(ethylcarbamate) 
• 1422377-07-8 (3-(4-chlorophenyl)-6-methyl-6,11-dihydro-5H-indolizino[6,7-b]indole-1,2-diyl)dimethanol 
• 1422376-98-4 dimethyl 3-(4-chlorophenyl)-6-methyl-6,11-dihydro-5H-indolizino-[6,7-b]indole-1,2-dicarboxylate 

Relevant articles and documents

Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase i and II inhibition

A series of bis(hydroxymethyl)indolizino[6,7-b]indoles and their bis(alkylcarbamates) were synthesized for antitumor studies. These agents were designed as hybrid molecules of β-carboline (topoisomerase inhibition moiety) and bis(hydroxymethyl)pyrrole (DNA cross-linking moiety). The preliminary antitumor studies indicated that these agents exhibited significant cytotoxicity against a variety of human tumor cells in vitro. Treatment of human breast carcinoma MX-1 xenograft-bearing nude mice with compounds 18b and 28c achieved more than 99% tumor remission. We also observed that 18a displayed potent therapeutic efficacy against human lung adenocarcinoma A549 and colon cancer HT-29 xenografts. These results revealed that compound 18a was more potent than irinotecan against HT-29 cells and was as potent as irinotecan against A549 cells in xenograft models. Furthermore, we demonstrated that these derivatives possess multiple modes of action, such as induction of DNA cross-linking, inhibition of topoisomerase I and II, and cell-cycle arrest at the S-phase.